MicroPort® NeuroTech Attends 15th CFCVD

Beijing, China – From April 12 to April 15, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the 15th China Forum of Cerebrovascular Diseases ("CFCVD") held in Beijing. The CFCVD is one of the most premier academic events in China's cerebrovascular diseases field, covering intracranial stent, arterial aneurysm, AVM, carotid artery lesion, thrombectomy, severe case treatment, nursing, and other interventional and surgical treatment of cerebrovascular diseases.
In the session of arterial aneurysm, Professor Xiaodong Xie of West China Hospital of Sichuan University gave a presentation on safety and efficacy of WILLIS® Intracranial Stent Graft System ("WILLIS®"). Researched and developed independently by MicroPort® NeuroTech, WILLIS® is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China, and also the first medical device to achieve complete vascular reconstruction in China. WILLIS® vascular reconstruction achieves complete occlusion, and unlike traditional treatment using stent-assisted coil embolization, WILLIS® effectively shunts the blood flow and keeps it off of the aneurysm wall. Based on his clinical cases in West China Hospital, Professor Xie spoke highly of the excellent performance of WILLIS®, and had active interaction with experts in attendance regarding their clinical experience with WILLIS®.
MicroPort® NeuroTech also displayed its innovative product - Tubridge® Vascular Reconstruction Device ("Tubridge®"), that was newly granted the approval from China Food and Drug Administration ("CFDA"), which attracted a lot of attendees to inquire for product information. Tubridge® is the first China-developed intracranial stent with densely meshed wire braids. It is designed for the treatment of large and giant cerebral aneurysm. The device cures the cerebral aneurysm by effectively diverting the blood flow based on the hemodynamics, reducing the impact of blood flow to the cerebral aneurysm, and enabling the endothelial cells to grow along the stent struts and gradually repair aneurysmal neck. The clinical performance of Tubridge® gained high recognition from experts in attendance and they expressed their expectation on its future clinical application.